Finance Report 2020 Roche Group 1
FINANCE REPORT Roche | Finance | Report F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland © 2021 2020 All trademarks are legally protected. www.roche.com 7 001 038 E 2020 Finance in Brief Key results Sales Core operating prot margin CER growth % % of sales Pharmaceuticals –2.4 43.7 +10.7 43.3 Diagnostics +13.9 18.6 2019 +2.9 15.2 Group +1.0 36.9 2019 +8.9 36.6 2020 2019 % change % of sales (CHF m) (CHF m) (CHF) (CER) 2020 2019 IFRS results Sales 58,323 61,466 –5 +1 Operating profit 18,543 17,548 +6 +16 31.8 28.5 Net income 15,068 14,108 +7 +17 25.8 23.0 Net income attributable to Roche shareholders 14,295 13,497 +6 +17 24.5 22.0 Diluted EPS (CHF) 16.52 15.62 +6 +17 Dividend per share (CHF) 9.10a) 9.00 +1 Core results Research and development 12,153 11,696 +4 +8 20.8 19.0 Core operating profit 21,536 22,479 –4 +4 36.9 36.6 Core EPS (CHF) 19.16 20.16 –5 +4 Free cash flow Operating free cash flow 14,815 20,921 –29 –21 25.4 34.0 Free cash flow 10,943 16,764 –35 –26 18.8 27.3 2020 2019 % change (CHF m) (CHF m) (CHF) (CER) Net debt (1,882) (2,505) –25 –2 Capitalisation 53,989 50,230 +7 +14 – Debt 14,216 14,363 –1 +6 – Equity 39,773 35,867 +11 +17 a) Proposed by the Board of Directors.
[Show full text]